RELIEF: Safety and Efficacy of Licaminlimab Ophthalmic Suspension for the Treatment of Dry Eye Disease (clinicaltrials.gov) - Dec 8, 2023 - P2 | N=120 | Recruiting | Sponsor: Oculis | Not yet recruiting ➔ Recruiting
Enrollment open • Dry Eye Disease • Ophthalmology
|